The Five Most Commonly Used Intact Parathyroid Hormone Assays Are Useful for Screening but Not for Diagnosing Bone Turnover Abnormalities in CKD-5 Patients

Overview

Journal Clin Nephrol

Specialty Nephrology

Date 2009 Jul 31

PMID 19640382

Citations 13

Authors

J Herberth

M-C Monier-Faugere

H W Mawad

A J Branscum

Z Herberth

G Wang

T Cantor

H H Malluche

Affiliations

Soon will be listed here.

Abstract

Background/aims: Assessment of bone turnover for management of renal osteodystrophy is part of routine care in chronic kidney disease Stage 5 (CKD-5) patients. Measurement of intact parathyroid hormone (iPTH) is the most commonly used surrogate marker for bone turnover in these patients. The current study was conducted to evaluate the predictive value of the five most commonly used iPTH assays for bone turnover.

Methods: In a cross-sectional study, 84 CKD-5 patients underwent bone biopsy and blood drawings for determination of iPTH and total serum alkaline phosphatase (AP).

Results: Histologically, patients presented with a broad range of bone turnover abnormalities as determined by activation frequency and bone formation rate/bone surface. Results of the five iPTH assays in each patient correlated but were significantly different. There were also significant differences between iPTH measurements at the same bone turnover level. Using Kidney Disease Outcome Quality Initiative recommended iPTH ranges, all assays showed comparably poor diagnostic performance. At 80% specificity, cut-off values of the 5 iPTH assays for low bone turnover varied from 165 to 550 pg/ml and for high bone turnover from 404 to 1,003 pg/ml. Sensitivities at these cutoffs remained below acceptable standards. Addition of AP measurements to iPTH did not improve diagnostic accuracy.

Conclusions: Precise assessment of bone turnover will require utilization of established and novel bone markers reflecting effects of bone turnover rather than measuring only iPTH or other effectors.

Citing Articles

Advanced glycosylation end products promote the progression of CKD-MBD in rats, and its natural inhibitor, quercetin, mitigates disease progression.

Wang Y, Hu C, Cao L, Liu Q, Li Y, Zhu T Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9675-9688.

PMID: 38907848 DOI: 10.1007/s00210-024-03217-1.

Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease.

Raji Y, Ajayi S, Adeoye A, Amodu O, Tayo B, Salako B Afr Health Sci. 2022; 22(1):344-351.

PMID: 36032486 PMC: 9382529. DOI: 10.4314/ahs.v22i1.42.

Prevalence of Renal Osteodystrophy and its Related Factors among End-stage Renal Disease Patients Undergoing Hemodialysis: Report from Imam Reza Referral Hospital of Medical University of Kermanshah, Iran.

Seyedzadeh A, Tohidi M, Golmohamadi S, Omrani H, Seyedzadeh M, Amiri S Oman Med J. 2022; 37(1):e335.

PMID: 35136664 PMC: 8804157. DOI: 10.5001/omj.2021.120.

Comparison of Second- and Third-Generation Parathyroid Hormone Test Results in Patients with Chronic Kidney Disease.

Wojtowicz M, Piechota W, Wankowicz Z, Smoszna J, Niemczyk S Med Sci Monit. 2020; 26:e928301.

PMID: 33361742 PMC: 7771203. DOI: 10.12659/MSM.928301.

Higher Proportion of Non-1-84 PTH Fragments in Peritoneal Dialysis Patients Compared to Hemodialysis Patients Using Solutions Containing 1.75 mmol/l Calcium.

Sanchez-Gonzalez C, Gonzalez-Casaus M, Sellares V, Albalate M, Torregrosa J, Mas S Front Physiol. 2018; 9:1643.

PMID: 30524306 PMC: 6262178. DOI: 10.3389/fphys.2018.01643.

References

Qi Q, Monier-Faugere M, Geng Z, Malluche H . Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995; 26(4):622-31. DOI: 10.1016/0272-6386(95)90599-5. View

Bervoets A, Spasovski G, Behets G, Dams G, Polenakovic M, Zafirovska K . Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003; 41(5):997-1007. DOI: 10.1016/s0272-6386(03)00197-5. View

Malluche H, Ritz E, LANGE H, Kutschera L, Hodgson M, Seiffert U . Bone histology in incipient and advanced renal failure. Kidney Int. 1976; 9(4):355-62. DOI: 10.1038/ki.1976.42. View

Martin K, Olgaard K, Coburn J, Coen G, Fukagawa M, Langman C . Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 2004; 43(3):558-65. DOI: 10.1053/j.ajkd.2003.12.003. View

Nussbaum S, Zahradnik R, Lavigne J, Brennan G, Kim L, Keutmann H . Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem. 1987; 33(8):1364-7. View

Manning R, Hendy G, Papapoulos S, ORIORDAN J . Development of homologous immunological assays for human parathyroid hormone. J Endocrinol. 1980; 85(1):161-70. DOI: 10.1677/joe.0.0850161. View

Monier-Faugere M, Geng Z, Mawad H, FRIEDLER R, Gao P, Cantor T . Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001; 60(4):1460-8. DOI: 10.1046/j.1523-1755.2001.00949.x. View

Herberth J, Fahrleitner-Pammer A, Obermayer-Pietsch B, Krisper P, Holzer H, Malluche H . Changes in total parathyroid hormone (PTH), PTH-(1-84) and large C-PTH fragments in different stages of chronic kidney disease. Clin Nephrol. 2006; 65(5):328-34. DOI: 10.5414/cnp65328. View

Cantor T, Yang Z, Caraiani N, Ilamathi E . Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem. 2006; 52(9):1771-6. DOI: 10.1373/clinchem.2006.071589. View

10.

Cantor T . Parathyroid hormone assay drift: an unappreciated problem in dialysis patient management. Semin Dial. 2005; 18(5):359-64. DOI: 10.1111/j.1525-139X.2005.00073.x. View

11.

MALLUCHE H, Faugere M . Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int. 1990; 38(2):193-211. DOI: 10.1038/ki.1990.187. View

12.

Ritz E, Krempien B, Mehls O, MALLUCHE H . Skeletal abnormalities in chronic renal insufficiency before and during maintenance hemodialysis. Kidney Int. 1973; 4(2):116-27. DOI: 10.1038/ki.1973.90. View

13.

Whitham K . External quality assessment of bone metabolism marker assays. initial experiences in a UK NEQAS programme. Clin Chem Lab Med. 2001; 38(11):1121-4. DOI: 10.1515/CCLM.2000.168. View

14.

Malluche H, Meyer W, Sherman D, Massry S . Quantitative bone histology in 84 normal American subjects. Micromorphometric analysis and evaluation of variance in iliac bone. Calcif Tissue Int. 1982; 34(5):449-55. DOI: 10.1007/BF02411283. View

15.

Segre G, Niall H, Sauer R, Potts Jr J . Edman degradation of radioiodinated parathyroid hormone: application to sequence analysis and hormone metabolism in vivo. Biochemistry. 1977; 16(11):2417-27. DOI: 10.1021/bi00630a017. View

16.

Fischer J, Binswanger U, DIETRICH F . Human parathyroid hormone. Immunological characterization of antibodies against a glandular extract and the synthetic amino-terminal fragments 1-12 and 1-34 and their use in the determination of immunoreactive hormone in human sera. J Clin Invest. 1974; 54(6):1382-94. PMC: 301693. DOI: 10.1172/JCI107885. View

17.

. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201. View

18.

Martin K, Hruska K, Freitag J, KLAHR S, Slatopolsky E . The peripheral metabolism of parathyroid hormone. N Engl J Med. 1979; 301(20):1092-8. DOI: 10.1056/NEJM197911153012005. View

19.

Urena P, De Vernejoul M . Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int. 1999; 55(6):2141-56. DOI: 10.1046/j.1523-1755.1999.00461.x. View

20.

MAYER G, Keaton J, HURST J, Habener J . Effects of plasma calcium concentration on the relative proportion of hormone and carboxyl fragments in parathyroid venous blood. Endocrinology. 1979; 104(6):1778-84. DOI: 10.1210/endo-104-6-1778. View